Breaking News, Financial News

Piramal Pharma Revenue Increases 12% YoY in Q1

Its CDMO Business and India Consumer Healthcare Business both grew double digits.

Author Image

By: Charlie Sternberg

Associate Editor

Piramal Pharma Limited has shared its financial results for the first quarter ended June 30th, 2024. Revenue from Operations grew by 12% YoY in Q1FY25, driven by robust high-teen growth in the CDMO business and steady double-digit growth in the India Consumer Healthcare Business (ICH) business. The Complex Hospital Generic (CHG) business grew 2% YoY. Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We have had a good start to the financial year with a steady all-round performa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters